Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
This randomized, double‑blind, cross‑over trial gave 51 patients with life‑threatening cancer two sessions of psilocybin (one very low dose and one high dose) spaced five weeks apart. The high dose (22–30 mg/70 kg) produced large drops in clinician‑ and self‑rated depression and anxiety, and increased quality of life, meaning, and…
In this small, double-blind, placebo-controlled crossover study, 10 healthy male, infrequent cannabis users took 10 mg oral THCV daily for five days and then received 1 mg IV THC on day five. THCV was safe and felt like placebo. Compared with placebo, THCV reduced some effects of THC (for example…
Researchers reviewed 19 placebo-controlled studies that tested low doses of LSD or psilocybin (this is called microdosing). The studies found measurable changes in brain biology, body responses, how people felt, and how they thought, compared with placebo. But the studies are few and small, often tested only tiny doses in…
We provide further preliminary evidence for the efficacy and tolerability of IM ketamine in an outpatient cohort of OCD. Additional work is required to establish the optimal dosing regimen and longer-term role of ketamine for OCD. These findings are encouraging given the well-known limitations that exist for treatments in this…
